<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="815">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575146</url>
  </required_header>
  <id_info>
    <org_study_id>ERGO</org_study_id>
    <nct_id>NCT00575146</nct_id>
  </id_info>
  <brief_title>Ketogenic Diet for Recurrent Glioblastoma</brief_title>
  <acronym>ERGO</acronym>
  <official_title>Ketogenic Diet for Patients With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Evomed MedizinService GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether a mild ketogenic diet can influences quality of life and survival of
      patients with recurrent glioblastoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increased glycolysis and reduced oxidative phosphorylation is a characteristic property of
      many tumors. A change of nutrition by limiting carbohydrates and increasing the proportion
      of fatty acids and proteins can lead to ketogenic metabolism and might limit energy
      production in tumor cells and therefore inhibit tumor growth. Standard treatment for
      glioblastoma includes resection, irradiation and temozolomide chemotherapy. If there is
      tumor recurrence, no standard therapy is established. Therapeutic options in this situation
      include resection, irradiation or another chemotherapy. However, some patients cannot be
      treated in this situation, because none of the available treatment options seems reasonable
      or applicable, for example if no additional chemotherapy can be started at the time of
      recurrence due to myelosuppression. The pilot study examines whether in this situation a
      ketogenic diet can be applied to the patients and may inhibit tumor growth and influence the
      quality of life of the patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Applicability as Measured by Discontinuation of Study Treatment Due to Intolerability</measure>
    <time_frame>until progression for up to 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>percentage of patients who discontinued diet due to intolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free-survival</measure>
    <time_frame>until progression for up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>measured by Macdonald-Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>death/last contact, an average of about 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants were followed until reported death or last contact until 05/2011</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Seizures</measure>
    <time_frame>while on study treatment for up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ketosis</measure>
    <time_frame>while on study treatment for up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>while on study treatment for up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketogenic diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>TAVARLIN</intervention_name>
    <description>ketogenic diet, dietary supplementary products provided by TAVARLIN</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;= 18 years

          -  histological diagnosis of glioblastoma or gliosarcoma

          -  on MRI measurable tumor

          -  interval of at least 6 months after primary resection

          -  completed radiotherapy, interval of at least 3 months after completion of
             radiotherapy

          -  relapse during or after temozolomide chemotherapy, other chemotherapy not possible,
             not reasonable or not wanted by the patient

          -  Karnofsky-Index &gt;= 60%, ECOG &lt;= 2

          -  life expectancy of at least 12 weeks

          -  creatinine &lt;= 1.5 mg/dl, urea &lt;= 50 mg/dl

          -  INR &lt;= 1,5, GOT &lt;= 7 x of normal value, GPT &lt;= 7 x of normal value

        Exclusion Criteria:

          -  bowel obstruction or subileus

          -  diabetes mellitus, HbA1c &gt; 6,1 %

          -  heart failure (NYHA &gt; 2), myocardial infarction within the last 6 months, atrial
             fibrillation

          -  acute infection

          -  conditions that may strongly reduce compliance to the diet or increase risk of the
             diet

          -  dementia or clinically relevant alterations of the mental state which interfere with
             the applicability of the diet
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Rieger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senckenberg Institute of Neurooncology, University of Frankfurt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Senckenberg Institute of Neurooncology</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of General Neurology and Hertie-Institute of Clinical Brain Research, University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M, Steinbach JP. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014 Jun;44(6):1843-52. doi: 10.3892/ijo.2014.2382. Epub 2014 Apr 11. Erratum in: Int J Oncol. 2014 Dec;45(6):2605.</citation>
    <PMID>24728273</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>December 17, 2007</firstreceived_date>
  <firstreceived_results_date>June 18, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>J. Rieger</investigator_full_name>
    <investigator_title>Dr. Johannes Rieger</investigator_title>
  </responsible_party>
  <keyword>glioblastoma</keyword>
  <keyword>ketogenic diet</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketogenic Diet</title>
          <description>unrestricted ketogenic diet (&lt; 50-60 g carbohydrates per day) and dietary supplementary products provided by Tavarlin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketogenic Diet</title>
          <description>ketogenic diet</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="55" spread="12.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Applicability as Measured by Discontinuation of Study Treatment Due to Intolerability</title>
        <description>percentage of patients who discontinued diet due to intolerability</description>
        <time_frame>until progression for up to 12 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ketogenic Diet</title>
            <description>unrestricted ketogenic diet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Applicability as Measured by Discontinuation of Study Treatment Due to Intolerability</title>
            <description>percentage of patients who discontinued diet due to intolerability</description>
            <units>percent of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free-survival</title>
        <description>measured by Macdonald-Criteria</description>
        <time_frame>until progression for up to 12 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>for the analyis of PFS and OS, 3 patients who discontinued the diet in the absence of progression were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Ketogenic Diet</title>
            <description>unrestricted ketogenic diet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression-free-survival</title>
            <description>measured by Macdonald-Criteria</description>
            <units>weeks</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5" lower_limit="3" upper_limit="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Participants were followed until reported death or last contact until 05/2011</description>
        <time_frame>death/last contact, an average of about 1 year</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ketogenic Diet</title>
            <description>unrestricted ketogenic diet</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Survival</title>
            <description>Participants were followed until reported death or last contact until 05/2011</description>
            <units>weeks</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="32" lower_limit="6" upper_limit="159"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Seizures</title>
        <time_frame>while on study treatment for up to 12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ketosis</title>
        <time_frame>while on study treatment for up to 12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <time_frame>while on study treatment for up to 12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Because of the small number of patients efficacy cannot be concluded by the results of the study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Johannes Rieger</name_or_title>
      <organization>Dr. Senckenberg Institute of Neurooncology</organization>
      <phone>+49 69 6301 ext 87711</phone>
      <email>johannes.rieger@med.uni-frankfurt.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
